keyword
MENU ▼
Read by QxMD icon Read
search

breast neoadjuvant chemotherapy

keyword
https://www.readbyqxmd.com/read/29687878/anthracycline-and-trastuzumab-induced-cardiotoxicity-in-breast-cancer
#1
M A Nicolazzi, A Carnicelli, M Fuorlo, A Scaldaferri, R Masetti, R Landolfi, A M R Favuzzi
OBJECTIVE: Breast cancer is the most common cancer among women. In the last twenty years early diagnosis, neoadjuvant and adjuvant systemic treatment that targeted to specific molecular targets have significantly reduced the mortality from breast cancer. However, the increase in survival has allowed to observe the cardiotoxic effects of anticancer therapy and increased mortality from cardiovascular causes, resulting in a large literature where experts try to identify the correct management of this critical problem...
April 2018: European Review for Medical and Pharmacological Sciences
https://www.readbyqxmd.com/read/29685462/aldh1-and-tumor-infiltrating-lymphocytes-as-predictors-for-neoadjuvant-chemotherapy-response-in-breast-cancer
#2
Anbok Lee, Kyu Yeoun Won, Sung-Jig Lim, Sun Young Cho, Sang-Ah Han, SaeGwang Park, Jeong-Yoon Song
Many studies have reported that Aldehyde dehydrogenase 1 (ALDH1) and tumor-infiltrating lymphocytes (TIL) are related to breast cancer prognosis. However, the clinical significance of ALDH1 and tumor-infiltrating immune cells in breast cancer has not been fully investigated in patients who received neoadjuvant chemotherapy (NAC). We studied the significance of the expression of ALDH1 and the population of TIL for predicting the prognosis and chemotherapeutic response of patients with breast cancer who had received NAC...
April 18, 2018: Pathology, Research and Practice
https://www.readbyqxmd.com/read/29685400/comparing-the-performances-of-magnetic-resonance-imaging-size-vs-pharmacokinetic-parameters-to-predict-response-to-neoadjuvant-chemotherapy-and-survival-in-patients-with-breast-cancer
#3
Basak E Dogan, Qing Yuan, Roland Bassett, Inanc Guvenc, Edward F Jackson, Massimo Cristofanilli, Gary J Whitman
PURPOSE: To compare the value of dynamic contrast-enhanced magnetic resonance imaging-pharmacokinetic (PK) parameters vs tumor volume in predicting breast cancer neoadjuvant chemotherapy response (NACR) and patient survival. SUBJECTS AND METHODS: Sixty-six patients with locally advanced breast cancer who underwent breast MRI monitoring of NACR were retrospectively analyzed. We compared baseline transfer constant (Ktrans ), reflux rate contrast (kep ), and extracellular extravascular volume fraction (ve ) with the same parameters obtained at early postchemotherapy MRI, and examined model-independent changes in time-intensity curves (maximum slope, contrast enhancement ratio, and IAUC90)...
March 28, 2018: Current Problems in Diagnostic Radiology
https://www.readbyqxmd.com/read/29685151/digital-gene-expression-profiling-analysis-and-its-application-in-the-identification-of-genes-associated-with-improved-response-to-neoadjuvant-chemotherapy-in-breast-cancer
#4
Xiaozhen Liu, Gan Jin, Jiacheng Qian, Hongjian Yang, Hongchao Tang, Xuli Meng, Yongfeng Li
BACKGROUND: This study aimed to screen sensitive biomarkers for the efficacy evaluation of neoadjuvant chemotherapy in breast cancer. METHODS: In this study, Illumina digital gene expression sequencing technology was applied and differentially expressed genes (DEGs) between patients presenting pathological complete response (pCR) and non-pathological complete response (NpCR) were identified. Further, gene ontology and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis were then performed...
April 23, 2018: World Journal of Surgical Oncology
https://www.readbyqxmd.com/read/29681456/chemoresistance-evolution-in-triple-negative-breast-cancer-delineated-by-single-cell-sequencing
#5
Charissa Kim, Ruli Gao, Emi Sei, Rachel Brandt, Johan Hartman, Thomas Hatschek, Nicola Crosetto, Theodoros Foukakis, Nicholas E Navin
Triple-negative breast cancer (TNBC) is an aggressive subtype that frequently develops resistance to chemotherapy. An unresolved question is whether resistance is caused by the selection of rare pre-existing clones or alternatively through the acquisition of new genomic aberrations. To investigate this question, we applied single-cell DNA and RNA sequencing in addition to bulk exome sequencing to profile longitudinal samples from 20 TNBC patients during neoadjuvant chemotherapy (NAC). Deep-exome sequencing identified 10 patients in which NAC led to clonal extinction and 10 patients in which clones persisted after treatment...
April 13, 2018: Cell
https://www.readbyqxmd.com/read/29680464/-radiotherapy-of-primary-breast-sarcomas-retrospective-study
#6
M Chellakhi, N Benchakroun, Z Bouchbika, H Jouhadi, N Tawfiq, S Sahraoui, A Benider
PURPOSE: Primary breast sarcomas are heterogeneous tumours derived from non-epithelial mammary gland structures. Although they represent a rare entity, their incidence may increase in the coming years owing to conservative approach considered in the treatment of breast cancer. The aim of this work was to highlight the effect of postoperative irradiation in the treatment of these tumours. MATERIALS AND METHODS: This is a retrospective study conducted at the Mohammed-VI centre for cancer treatment between 2004 and 2011...
April 18, 2018: Cancer Radiothérapie: Journal de la Société Française de Radiothérapie Oncologique
https://www.readbyqxmd.com/read/29679201/utilization-of-the-21-gene-recurrence-score-in-a-diverse-breast-cancer-patient-population-development-of-a-clinicopathologic-model-to-predict-high-risk-scores-and-response-to-neoadjuvant-chemotherapy
#7
Ko Un Park, Yalei Chen, Dhananjay Chitale, Sarah Choi, Haythem Ali, S David Nathanson, Jessica Bensenhaver, Erica Proctor, Lindsay Petersen, Randa Loutfi, Alyson Simonds, Marcia Kuklinski, Thomas Doyle, Vrushali Dabak, Kim Cole, Melissa Davis, Lisa Newman
INTRODUCTION: The 21-gene expression profile [Oncotype DX Recurrence Score (RS)] stratifies benefit from adjuvant chemotherapy in hormone receptor (HR)-positive, HER2/neu-negative, node-negative breast cancer. It is not routinely applied to predict neoadjuvant chemotherapy (NACT) response; data in diverse patient populations also are limited. We developed a statistical model based on standard clinicopathologic features to identify high-risk cases (RS > 30) and then evaluated ability of predicted high RS to predict for NACT downstaging...
April 20, 2018: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/29678165/retrospective-analysis-of-the-impact-of-anthracycline-dose-reduction-and-chemotherapy-delays-on-the-outcomes-of-early-breast-cancer-molecular-subtypes
#8
Sigita Liutkauskiene, Saulius Grizas, Kristina Jureniene, Jorune Suipyte, Akvile Statnickaite, Elona Juozaityte
BACKGROUND: The objective of study was to determine the effect of anthracycline dose reduction and chemotherapy delays on 5-year overall survival in patients with stage I-III breast cancer, to establish the impact of molecular subtypes on the anthracycline modification effects and to analyze reasons for such chemotherapy scheme modifications. METHODS: Medical records of patients with stage I-III breast cancer were reviewed. Inclusion criteria involved stage I- III breast carcinoma; radical surgery performed and 4 courses of AC regimen (doxorubicin and cyclophosphamide), or at least 6 courses of FAC regimen (fluorouracil, doxorubicin and cyclophosphamide) completed; no neoadjuvant chemotherapy applied; no taxane group medications administered; medical records maintain comprehensive data on treatment and follow-up...
April 20, 2018: BMC Cancer
https://www.readbyqxmd.com/read/29671222/prognostic-value-of-ki-67-according-to-age-in-patients-with-triple-negative-breast-cancer
#9
V Zenzola, M A Cabezas-Quintario, M Arguelles, E Pérez-Fernández, Y Izarzugaza, A Correa, J García-Foncillas
PURPOSE: The prognostic value of Ki-67 in triple-negative breast cancer (TNBC) is yet unclear because the cut-off points employed differ widely and its predictive effect may vary according to age. The purpose of this study was to analyze the role of Ki-67 among patients with TNBC, and determine the optimal Ki-67 cut-off point to demonstrate its prognostic relevance associated with patient age and treatment strategy. METHODS/PATIENTS: 201 consecutive patients treated for primary TNBC from 1999 to 2014 were analyzed...
April 18, 2018: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/29671138/nipple-sparing-mastectomy-is-not-associated-with-a-delay-of-adjuvant-treatment
#10
Emily L Albright, Mary C Schroeder, Kendra Foster, Sonia L Sugg, Lillian M Erdahl, Ronald J Weigel, Ingrid M Lizarraga
BACKGROUND: High-volume single-institution studies support the oncologic safety of nipple sparing mastectomy (NSM). Concerns remain regarding the increased potential for complications, recurrence, and delays to subsequent adjuvant therapy. A national database was used to examine treatment and outcomes for NSM patients. METHODS: Women undergoing unilateral NSM or skin sparing mastectomy (SSM) for stage 0-4 breast cancer from 2004 to 2013 were identified from the National Cancer Database...
April 18, 2018: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/29670372/postmastectomy-radiotherapy-reduces-locoregional-and-disease-recurrence-in-patients-with-stage-ii-iii-triple-negative-breast-cancer-treated-with-neoadjuvant-chemotherapy-and-mastectomy
#11
Xingxing Chen, Fan Xia, Jurui Luo, Jinli Ma, Zhaozhi Yang, Li Zhang, Yan Feng, Zhimin Shao, Xiaoli Yu, Xiaomao Guo
Background: This study investigated the effect of postmastectomy radiotherapy (PMRT) in patients with stage II-III triple-negative breast cancer (TNBC) after neoadjuvant chemotherapy (NAC) and modified radical mastectomy (MRM). Patients and methods: A total of 104 women with stage II-III TNBC who received NAC and MRM at our institution between January 2000 and July 2007 were identified. Patients were divided into 2 groups (PMRT and non-PMRT) for statistical analysis...
2018: OncoTargets and Therapy
https://www.readbyqxmd.com/read/29669584/mri-based-response-patterns-during-neoadjuvant-chemotherapy-can-predict-pathological-complete-response-in-patients-with-breast-cancer
#12
Briete Goorts, Kelly M A Dreuning, Janneke B Houwers, Loes F S Kooreman, Evert-Jan G Boerma, Ritse M Mann, Marc B I Lobbes, Marjolein L Smidt
BACKGROUND: The main purpose was to investigate the correlation between magnetic resonance imaging (MRI)-based response patterns halfway through neoadjuvant chemotherapy and immunotherapy (NAC) and pathological tumor response in patients with breast cancer. Secondary purposes were to compare the predictive value of MRI-based response patterns measured halfway through NAC and after NAC and to measure interobserver variability. METHODS: All consecutive patients treated with NAC for primary invasive breast cancer from 2012 to 2015 and who underwent breast MRI before, halfway through (and after) NAC were included...
April 18, 2018: Breast Cancer Research: BCR
https://www.readbyqxmd.com/read/29667115/biopsy-feasibility-trial-for-breast-cancer-pathologic-complete-response-detection-after-neoadjuvant-chemotherapy-imaging-assessment-and-correlation-endpoints
#13
Gaiane M Rauch, Henry M Kuerer, Beatriz Adrada, Lumarie Santiago, Tanya Moseley, Rosalind P Candelaria, Elsa Arribas, Jia Sun, Jessica W T Leung, Savitri Krishnamurthy, Wei T Yang
PURPOSE: This study was designed to present the secondary imaging endpoints of the trial for evaluating mammogram (MMG), ultrasound (US) and image guided biopsy (IGBx) assessment of pathologic complete response (pCR) in breast cancer (BC) patients undergoing neoadjuvant chemotherapy (NAC). METHODS: Patients with T1-3, N0-3, M0 triple-negative or HER2-positive BC who received NAC were enrolled in an Institutional Review Board-approved prospective, clinical trial...
April 17, 2018: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/29663173/current-status-of-neoadjuvant-endocrine-therapy-in-early-stage-breast-cancer
#14
REVIEW
Tomás Reinert, Rodrigo Gonçalves, Matthew J Ellis
Neoadjuvant endocrine therapy (NET) with Ki67-based response monitoring is a practical, cost-effective approach to the management of clinical stage II and III estrogen receptor-positive (ER+) breast cancer. In addition to marked improvements in rates of breast conservation, the identification of extreme responders on the basis of the preoperative endocrine prognostic index (PEPI) provides a rationale to avoid chemotherapy on the basis of highly favorable prognosis in some patients. Finally, samples accrued from patients treated with neoadjuvant therapy are providing valuable insights into the molecular basis for intrinsic resistance to endocrine therapy and promise a more rational basis and precise approach to the systemic treatment of ER+ breast cancer...
April 16, 2018: Current Treatment Options in Oncology
https://www.readbyqxmd.com/read/29662649/-18-fdg-pet-ct-and-molecular-markers-to-predict-response-to-neoadjuvant-chemotherapy-and-outcome-in-her2-negative-advanced-luminal-breast-cancers-patients
#15
Patricia de Cremoux, Lucie Biard, Brigitte Poirot, Philippe Bertheau, Luis Teixeira, Jacqueline Lehmann-Che, Fatiha A Bouhidel, Pascal Merlet, Marc Espié, Matthieu Resche-Rigon, Christos Sotiriou, David Groheux
Background: The efficacy of neoadjuvant chemotherapy regimens in advanced luminal breast cancer patients is difficult to predict. Intrinsic properties of breast tumors, including altered gene expression profile and dynamic evaluation of metabolic properties of tumor cells using positron emission tomography/computed tomography (PET/CT) of tumor cells, have been identified to guide patient's prognosis. The aim of this study is to determine if both analyses may improve the prediction of response to neoadjuvant chemotherapy in ER-positive / HER2-negative breast cancers (BCs) patients...
March 27, 2018: Oncotarget
https://www.readbyqxmd.com/read/29662529/neoadjuvant-chemotherapy-in-locally-advanced-duodenal-adenocarcinoma
#16
Carlos Velandia, Rafael Delgado Morales, Carlos Coello, Armando Gil Mendoza, Gabriel Pérez, Emperatriz Aguero
Duodenal adenocarcinoma (ADC) represents only 0.3% of gastrointestinal neoplasms. With the frequency being higher between the ages of 40 and 60, it is predominantly located in the second part of the duodenum and around the periampullary region. Symptoms are nonspecific, so the majority of patients present with advanced disease. Neoadjuvant chemotherapy is a therapeutic option that has not been well studied. The global literature includes only isolated reports on this subject. This is why we are presenting the following case: a 60-year-old female patient with a locally advanced, inoperable duodenal ADC received neoadjuvant chemotherapy...
2018: Ecancermedicalscience
https://www.readbyqxmd.com/read/29661243/effect-of-neoadjuvant-chemotherapy-regimen-on-relapse-free-survival-among-patients-with-breast-cancer-achieving-a-pathologic-complete-response-an-early-step-in-the-de-escalation-of-neoadjuvant-chemotherapy
#17
Anna Weiss, Sami I Bashour, Kenneth Hess, Alastair M Thompson, Nuhad K Ibrahim
BACKGROUND: Patients with breast cancer who have a pathologic complete response (pCR) to neoadjuvant chemotherapy (NACT) have improved survival. We hypothesize that once pCR has been achieved, there is no difference in subsequent postsurgical recurrence-free survival (RFS), whichever NACT regimen is used. METHODS: Data from patients with breast cancer who achieved pCR after NACT between 1996 and 2011 were reviewed. RFS was estimated by the Kaplan-Meier method, and differences between groups were assessed using log-rank testing...
April 16, 2018: Breast Cancer Research: BCR
https://www.readbyqxmd.com/read/29659933/circulating-tumor-cells-in-breast-cancer-patients-treated-by-neoadjuvant-chemotherapy-a-meta-analysis
#18
François-Clément Bidard, Stefan Michiels, Sabine Riethdorf, Volkmar Mueller, Laura J Esserman, Anthony Lucci, Bjørn Naume, Jun Horiguchi, Rafael Gisbert-Criado, Stefan Sleijfer, Masakazu Toi, Jose A Garcia-Saenz, Andreas Hartkopf, Daniele Generali, Françoise Rothé, Jeffrey Smerage, Laura Muinelo-Romay, Justin Stebbing, Patrice Viens, Mark Jesus M Magbanua, Carolyn S Hall, Olav Engebraaten, Daisuke Takata, José Vidal-Martínez, Wendy Onstenk, Noriyoshi Fujisawa, Eduardo Diaz-Rubio, Florin-Andrei Taran, Maria Rosa Cappelletti, Michail Ignatiadis, Charlotte Proudhon, Denise M Wolf, Jessica B Bauldry, Elin Borgen, Rin Nagaoka, Vicente Carañana, Jaco Kraan, Marisa Maestro, Sara Yvonne Brucker, Karsten Weber, Fabien Reyal, Dominic Amara, Mandar G Karhade, Randi R Mathiesen, Hideaki Tokiniwa, Antonio Llombart-Cussac, Alessandra Meddis, Paul Blanche, Koenraad d'Hollander, Klaus Pantel
Background: We conducted a meta-analysis in nonmetastatic breast cancer patients treated by neoadjuvant chemotherapy (NCT) to assess the clinical validity of circulating tumor cell (CTC) detection as a prognostic marker. Methods: We collected individual patient data from 21 studies in which CTC detection by CellSearch was performed in early breast cancer patients treated with NCT. The primary end point was overall survival, analyzed according to CTC detection, using Cox regression models stratified by study...
April 12, 2018: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/29659077/total-choline-quantification-measured-by-1h-mr-spectroscopy-as-early-predictor-of-response-after-neoadjuvant-treatment-for-locally-advanced-breast-cancer-the-impact-of-immunohistochemical-status
#19
Stylianos Drisis, Patrick Flamen, Michael Ignatiadis, Thierry Metens, Shih-Li Chao, Marie Chintinne, Marc Lemort
BACKGROUND: Validation of new biomarkers is essential for the early evaluation of neoadjuvant treatments. PURPOSE: To determine whether measurements of total choline (tCho) by 1H spectroscopy could predict morphological or pathological complete response (pCR) of neoadjuvant treatment and whether breast cancer subgroups are related to prediction accuracy. STUDY TYPE: Prospective, nonrandomized, monocentric, diagnostic study. POPULATION: Sixty patients were initially included with 39 women participating in the final cohort...
April 16, 2018: Journal of Magnetic Resonance Imaging: JMRI
https://www.readbyqxmd.com/read/29658333/mucinous-breast-carcinoma-with-tall-columnar-cells
#20
N Tsoukalas, M Kiakou, M Tolia, I D Kostakis, M Galanopoulos, G Nakos, D Tryfonopoulos, G Kyrgias, G Koumakis
Mucinous carcinoma of the breast represents 1%-4% of all breast cancers. The World Health Organization classification divides this type of tumour into three different subtypes: mucinous carcinoma, mucinous carcinoma with tall columnar cells (mucinous cystadenocarcinoma and columnar cell mucinous carcinoma) and signet ring cell carcinoma. A 74-year-old woman presented a tumour with inflammatory features in the upper outer quadrant of her left breast, 7 cm in diameter. The core biopsy showed infiltrating ductal carcinoma of no specific type...
April 16, 2018: Annals of the Royal College of Surgeons of England
keyword
keyword
55508
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"